BOSTON, MASSACHUSETTS, Jan. 22, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral ...

which is an inhaled inhibitor of galectin-3. Since then the US drugmaker has bolstered its early-stage research in fibrosis via academic partnerships with the California Institute for Biomedical ...

It has been shown that the ß-galactoside binding lectin galectin-3 can promote fibrosis through altering cellular responses to TGFß. 1 However, the precise mechanism of this is currently unknown.

Galectin-3 inhibitor, GLP-1 analog, inhibitors of VEGFR-2/PDGF-β, LOXL2 inhibitor, Pan-caspase inhibitor, a Phosphodiesterase inhibitor, and TGF-β signaling inhibitors. FIGURE 3. Potential candidates ...

for idiopathic pulmonary fibrosis (IPF). The trial evaluated deupirfenidone at two doses three times a day (TID) over 26 weeks in IPF patients. Participants in the trial were randomized 1:1:1:1 ...

Idiopathic Pulmonary Fibrosis (IPF) is a frightening ... On average, patients remained on the drug for only 10 months. 1 Professor Philip Molyneaux, consultant in interstitial lung disease ...

Galectin Therapeutics Inc.’s Stock Price as of Market Close As of January 15, 2025, 4:00 PM, CST, Galectin Therapeutics Inc.’s stock price was $1.280. Galectin Therapeutics Inc. is up 11.3% from its ...

PureTech Health plc (NASDAQ:PRTC – Get Free Report) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 24,600 shares, a decline ...

Their dysregulation is implicated in various diseases, including cancer, infectious diseases, and autoimmune disorders (1,2).One striking example of ... glycosylation (5).Within this landscape, the ...